RU2020121363A - APPLICATION OF GLUTARIMIDE DERIVATIVES FOR THERAPY OF DISEASES ASSOCIATED WITH ABERRANT INTERLEUKIN-6 ACTIVITY - Google Patents

APPLICATION OF GLUTARIMIDE DERIVATIVES FOR THERAPY OF DISEASES ASSOCIATED WITH ABERRANT INTERLEUKIN-6 ACTIVITY Download PDF

Info

Publication number
RU2020121363A
RU2020121363A RU2020121363A RU2020121363A RU2020121363A RU 2020121363 A RU2020121363 A RU 2020121363A RU 2020121363 A RU2020121363 A RU 2020121363A RU 2020121363 A RU2020121363 A RU 2020121363A RU 2020121363 A RU2020121363 A RU 2020121363A
Authority
RU
Russia
Prior art keywords
compound
syndrome
use according
imidazol
dione
Prior art date
Application number
RU2020121363A
Other languages
Russian (ru)
Other versions
RU2020121363A3 (en
RU2774928C2 (en
Inventor
Владимир Евгеньевич Небольсин
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Владимир Евгеньевич Небольсин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект", Владимир Евгеньевич Небольсин filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/en
Priority to RU2020121363A priority Critical patent/RU2774928C2/en
Priority to MA58653A priority patent/MA58653B1/en
Priority to CN202180044905.7A priority patent/CN115803026A/en
Priority to BR112022026356A priority patent/BR112022026356A2/en
Priority to PCT/RU2021/050170 priority patent/WO2021262040A1/en
Publication of RU2020121363A3 publication Critical patent/RU2020121363A3/ru
Publication of RU2020121363A publication Critical patent/RU2020121363A/en
Publication of RU2774928C2 publication Critical patent/RU2774928C2/en
Application granted granted Critical
Priority to CL2022003725A priority patent/CL2022003725A1/en
Priority to CONC2023/0000604A priority patent/CO2023000604A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (25)

1. Применение соединения 1-(2-(1-метил-1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы
Figure 00000001
или его соли, гидрата или сольвата для изготовления лекарственного средства для предупреждения и/или лечения расстройства, ассоциированного с аберрантной активностью интерлейкина-6 (Il-6).1. Use of compound 1- (2- (1-methyl-1H-imidazol-4-yl) ethyl) piperidine-2,6-dione of formula
Figure 00000001
or a salt, hydrate or solvate thereof for the manufacture of a medicament for the prevention and / or treatment of a disorder associated with the aberrant activity of interleukin-6 (Il-6). 2. Применение соединения 1-(2-(1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы
Figure 00000001
или его соли, гидрата или сольвата для изготовления лекарственного средства для предупреждения и/или лечения расстройства, связанного с развитием синдрома высвобождения цитокинов или цитокинового шторма.2. Use of compound 1- (2- (1H-imidazol-4-yl) ethyl) piperidine-2,6-dione of formula
Figure 00000001
or a salt, hydrate or solvate thereof for the manufacture of a medicament for the prevention and / or treatment of a disorder associated with the development of a cytokine release syndrome or cytokine storm. 3. Применение по п.2, где цитокин включает интерлейкин-6. 3. Use according to claim 2, wherein the cytokine comprises interleukin-6. 4. Применение по любому из пп.1-3, в котором расстройство выбрано из коронавирусной инфекции, COVID-19, острого респираторного дистресс-синдрома (ОРДС), сепсиса, реакции «трансплантат против хозяина», синдрома активации макрофагов, первичного и вторичного гемофагоцитарного лимфогистиоцитоза, осложнения иммунотерапии, такой как Т-клеточная терапия химерным рецептором антигена, и синдрома Кавасаки.4. Use according to any one of claims 1 to 3, wherein the disorder is selected from coronavirus infection, COVID-19, acute respiratory distress syndrome (ARDS), sepsis, graft versus host disease, macrophage activation syndrome, primary and secondary hemophagocytic lymphohistiocytosis, complications of immunotherapy such as chimeric antigen receptor T cell therapy, and Kawasaki syndrome. 5. Применение по любому из пп.4-7, где лекарственное средство содержит соединение в количестве от 30 до 500 мг.5. Use according to any one of claims 4 to 7, wherein the medicament contains the compound in an amount of 30 to 500 mg. 6. Применение по п.5, где лекарственное средство дополнительно содержит другой активный терапевтический агент.6. Use according to claim 5, wherein the medicament further comprises another active therapeutic agent. 7. Применение по п.6, где другой активный терапевтический агент выбран из группы, включающей глюкокортикостероид, противовирусное средство и моноклональное антитело.7. Use according to claim 6, wherein the other active therapeutic agent is selected from the group consisting of a glucocorticosteroid, an antiviral agent, and a monoclonal antibody. 8. Применение соединения 1-(2-(1-метил-1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы
Figure 00000001
или его соли, гидрата или сольвата для предупреждения и/или лечения расстройства, ассоциированного с аберрантной активностью интерлейкина-6 (Il-6).8. Use of compound 1- (2- (1-methyl-1H-imidazol-4-yl) ethyl) piperidine-2,6-dione of formula
Figure 00000001
or a salt, hydrate or solvate thereof for the prevention and / or treatment of a disorder associated with the aberrant activity of interleukin-6 (Il-6). 9. Применение соединения 1-(2-(1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы
Figure 00000001
или его соли, гидрата или сольвата для предупреждения и/или лечения расстройства, связанного с развитием синдрома высвобождения цитокинов или цитокинового шторма.9. Use of compound 1- (2- (1H-imidazol-4-yl) ethyl) piperidine-2,6-dione of formula
Figure 00000001
or a salt, hydrate or solvate thereof for the prevention and / or treatment of a disorder associated with the development of a cytokine release syndrome or cytokine storm. 10. Применение по п.9, где цитокин включает интерлейкин-6. 10. Use according to claim 9, wherein the cytokine comprises interleukin-6. 11. Применение по любому из пп.8-10, в котором расстройство выбрано из коронавирусной инфекции, COVID-19, острого респираторного дистресс-синдрома (ОРДС), сепсиса, реакции «трансплантат против хозяина», синдрома активации макрофагов, первичного и вторичного гемофагоцитарного лимфогистиоцитоза, осложнения иммунотерапии, такой как Т-клеточная терапия химерным рецептором антигена, и синдрома Кавасаки.11. Use according to any one of claims 8 to 10, wherein the disorder is selected from coronavirus infection, COVID-19, acute respiratory distress syndrome (ARDS), sepsis, graft versus host disease, macrophage activation syndrome, primary and secondary hemophagocytic lymphohistiocytosis, complications of immunotherapy such as chimeric antigen receptor T cell therapy, and Kawasaki syndrome. 12. Применение по любому из пп.8-11, где лекарственное средство содержит соединение в количестве от 30 до 500 мг.12. Use according to any one of claims 8 to 11, wherein the medicament contains the compound in an amount of from 30 mg to 500 mg. 13. Применение по п.12, где лекарственное средство дополнительно содержит другой активный терапевтический агент.13. Use according to claim 12, wherein the medicament further comprises another active therapeutic agent. 14. Применение по п.13, где другой активный терапевтический агент выбран из группы, включающей глюкокортикостероид, противовирусное средство и моноклональное антитело.14. Use according to claim 13, wherein the other active therapeutic agent is selected from the group consisting of a glucocorticosteroid, an antiviral agent, and a monoclonal antibody. 15. Фармацевтическая композиция для предупреждения и/или лечения расстройства, связанного с аберрантной активностью интерлейкина-6, содержащая от 0,01 до 99,99 мас.% соединения 1-(2-(1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы
Figure 00000001
или его соли, гидрата или сольвата и по меньшей мере один фармацевтически приемлемый носитель.15. A pharmaceutical composition for the prevention and / or treatment of a disorder associated with the aberrant activity of interleukin-6, containing from 0.01 to 99.99 wt.% Of compound 1- (2- (1H-imidazol-4-yl) ethyl) piperidine -2,6-dione of the formula
Figure 00000001
or a salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier. 16. Фармацевтическая композиция для предупреждения и/или лечения расстройства, связанного с развитием синдрома высвобождения цитокинов или цитокинового шторма, содержащая от 0,01 до 99,99 мас.% соединения 1-(2-(1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы16. A pharmaceutical composition for the prevention and / or treatment of a disorder associated with the development of a cytokine release syndrome or cytokine storm, containing from 0.01 to 99.99 wt.% Of the compound 1- (2- (1H-imidazol-4-yl) ethyl ) piperidine-2,6-dione of the formula
Figure 00000001
или его соли, гидрата или сольвата и по меньшей мере один фармацевтически приемлемый носитель.
Figure 00000001
or a salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier. 17. Фармацевтическая композиция по п.15 или 16 для лечения расстройства, которое выбрано из коронавирусной инфекции, COVID-19, острого респираторного дистресс-синдрома (ОРДС), сепсиса, реакции «трансплантат против хозяина», синдрома активации макрофагов, первичного и вторичного гемофагоцитарного лимфогистиоцитоза, осложнения иммунотерапии, такой как Т-клеточная терапия химерным рецептором антигена и синдрома Кавасаки.17. A pharmaceutical composition according to claim 15 or 16 for treating a disorder that is selected from coronavirus infection, COVID-19, acute respiratory distress syndrome (ARDS), sepsis, graft versus host reaction, macrophage activation syndrome, primary and secondary hemophagocytic lymphohistiocytosis, complications of immunotherapy such as chimeric antigen receptor T cell therapy, and Kawasaki syndrome. 18. Способ предупреждения и/или лечения расстройства, связанного с аберрантной активностью интерлейкина-6, включающий введение нуждающемуся субъекту соединения 1-(2-(1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы
Figure 00000001
или его соли, гидрата или сольвата.18. A method of preventing and / or treating a disorder associated with the aberrant activity of interleukin-6, comprising administering to a subject in need a compound 1- (2- (1H-imidazol-4-yl) ethyl) piperidine-2,6-dione of the formula
Figure 00000001
or a salt, hydrate or solvate thereof. 19. Способ предупреждения и/или лечения расстройства, связанного с развитием синдрома высвобождения цитокинов или цитокинового шторма, включающий введение нуждающемуся субъекту соединения 1-(2-(1Н-имидазол-4-ил)этил)пиперидин-2,6-диона формулы
Figure 00000001
или его соли, гидрата или сольвата.19. A method of preventing and / or treating a disorder associated with the development of a cytokine release syndrome or cytokine storm, comprising administering to a subject in need a compound 1- (2- (1H-imidazol-4-yl) ethyl) piperidine-2,6-dione of the formula
Figure 00000001
or a salt, hydrate or solvate thereof. 20. Способ по п.19, где цитокин включает интерлейкин-6. 20. The method of claim 19, wherein the cytokine comprises interleukin-6. 21. Способ по любому из пп.18-20, в котором расстройство выбрано из коронавирусной инфекции, COVID-19, острого респираторного дистресс-синдрома (ОРДС), сепсиса, реакции «трансплантат против хозяина», синдрома активации макрофагов, первичного и вторичного гемофагоцитарного лимфогистиоцитоза, осложнения иммунотерапии, такой как Т-клеточная терапия химерным рецептором антигена, и синдрома Кавасаки.21. The method according to any one of claims 18-20, wherein the disorder is selected from coronavirus infection, COVID-19, acute respiratory distress syndrome (ARDS), sepsis, graft versus host reaction, macrophage activation syndrome, primary and secondary hemophagocytic lymphohistiocytosis, complications of immunotherapy such as chimeric antigen receptor T cell therapy, and Kawasaki syndrome. 22. Способ по любому из пп.18-21, где соединение вводят нуждающемуся субъекту в количестве от 60 до 250 мг в сутки.22. A method according to any one of claims 18-21, wherein the compound is administered to a subject in need in an amount of 60 to 250 mg per day. 23. Способ по любому из пп.18-22, где соединение вводят нуждающемуся субъекту в сочетании с другим активным терапевтическим агентом.23. A method according to any one of claims 18-22, wherein the compound is administered to a subject in need in combination with another active therapeutic agent. 24. Способ по п.23, где другой активный терапевтический агент выбран из группы, включающей глюкокортикостероид, противовирусное средство и моноклональное антитело.24. The method of claim 23, wherein the other active therapeutic agent is selected from the group consisting of a glucocorticosteroid, an antiviral agent, and a monoclonal antibody.
RU2020121363A 2020-06-26 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 RU2774928C2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (en) 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6
PCT/RU2021/050170 WO2021262040A1 (en) 2020-06-26 2021-06-18 Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity
CN202180044905.7A CN115803026A (en) 2020-06-26 2021-06-18 Use of glutarimide derivatives for the treatment of diseases associated with abnormal interleukin-6 activity
BR112022026356A BR112022026356A2 (en) 2020-06-26 2021-06-18 USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES ASSOCIATED WITH ABERRANT INTERLEUKIN-6 ACTIVITY
MA58653A MA58653B1 (en) 2020-06-26 2021-06-18 USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY
CL2022003725A CL2022003725A1 (en) 2020-06-26 2022-12-22 Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity.
CONC2023/0000604A CO2023000604A2 (en) 2020-06-26 2023-01-19 Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (en) 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022116762A Division RU2022116762A (en) 2022-06-22 USE OF GLUTARIMIDE DERIVATIVE FOR THE THERAPY OF DISEASES ASSOCIATED WITH ABERRANT ACTIVITY OF INTERLEUKIN-6

Publications (3)

Publication Number Publication Date
RU2020121363A3 RU2020121363A3 (en) 2021-12-27
RU2020121363A true RU2020121363A (en) 2021-12-27
RU2774928C2 RU2774928C2 (en) 2022-06-27

Family

ID=

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809992C1 (en) * 2022-06-24 2023-12-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" New crystal form of 1-[2-(1-methylimidazol-4-yl)ethyl]perhydroazine-2,6-dione and its pharmaceutical use
WO2023249516A1 (en) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Novel crystalline form of 1-[2-(1-methylimidazole-4-yl)ethyl]perhydroazine-2,6-dione and pharmaceutical use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2819722C2 (en) * 2022-03-18 2024-05-23 Общество С Ограниченной Ответственностью "Валента - Интеллект" Use of 1-(2-(1n-imidazol-4-yl)ethyl)piperidine-2,6-dione for treating cough caused by viral infections
RU2809992C1 (en) * 2022-06-24 2023-12-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" New crystal form of 1-[2-(1-methylimidazol-4-yl)ethyl]perhydroazine-2,6-dione and its pharmaceutical use
WO2023249516A1 (en) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Novel crystalline form of 1-[2-(1-methylimidazole-4-yl)ethyl]perhydroazine-2,6-dione and pharmaceutical use thereof

Also Published As

Publication number Publication date
CO2023000604A2 (en) 2023-01-26
RU2020121363A3 (en) 2021-12-27
MA58653B1 (en) 2024-02-29
CL2022003725A1 (en) 2023-05-19
BR112022026356A2 (en) 2023-01-17
CN115803026A (en) 2023-03-14
MA58653A1 (en) 2023-07-31
WO2021262040A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US20170165266A1 (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
JP5450434B2 (en) How to treat arthritis
TWI821235B (en) Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
EA032430B1 (en) Fused pyrimidines for the treatment of hiv
JP2008504363A (en) Combination therapy using benzamide inhibitor of P2X7 receptor
WO2010081817A1 (en) Method for treating colorectal cancer
JP2007536241A (en) A2A adenosine receptor agonist for the treatment of diabetic nephropathy
TW202342026A (en) Jak1 pathway inhibitors for the treatment of cytokine-related disorders
EP0664128A1 (en) Pharmaceutical composition for inhibiting tumor necrosis factor production
JP2020114849A (en) Use of 2-carboxamide cycloamino urea derivatives in treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
JP3162071B2 (en) Cytokine inhibitor
Hendeles et al. Evaluation of cytokine modulators for asthma
RU2020121363A (en) APPLICATION OF GLUTARIMIDE DERIVATIVES FOR THERAPY OF DISEASES ASSOCIATED WITH ABERRANT INTERLEUKIN-6 ACTIVITY
EP3804724B1 (en) Cdk inhibitors for treating pah
Saeki et al. Successful management of a patient with Marfan syndrome complicated with acute aortic dissection using landiolol during Cesarean section
JPWO2021045159A5 (en)
RU2022116762A (en) USE OF GLUTARIMIDE DERIVATIVE FOR THE THERAPY OF DISEASES ASSOCIATED WITH ABERRANT ACTIVITY OF INTERLEUKIN-6
JP6511630B2 (en) Pharmaceutical composition for cancer prevention or cancer treatment, and method using the same
CN117320720A (en) Combination therapy using MALT1 inhibitors and BTK inhibitors
KR20080055914A (en) Regimen of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine
CN114430681A (en) Treatment of EGFR mutation-related cancers with combinations of EGFR and CDK4/6 inhibitors
WO2019053723A1 (en) A3 adenosine receptor ligand for managing cytokine release syndrome
CN113840601A (en) Combination therapy using bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JP2005531622A5 (en)
JP2013525296A (en) Treatment of endocrine therapy-resistant breast cancer